共 50 条
- [22] Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 103 - 112
- [25] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
- [26] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (02):
- [27] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
- [29] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
- [30] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):